Your Messages Inbox
Your Article Summary
See Latest ArticlesMyriad Genetics, Inc. Receives Approval From New York Stock Exchange to Proceed With New Listing
Myriad, 04/16/09
Myriad Genetics, Inc. announced that the NYSE's Listing and Compliance Committee has received Myriad's eligibility materials and cleared it to file an application to transfer trading of Myriad's shares to the New York Stock Exchange from NASDAQ. Myriad Genetics anticipates trading on the NYSE Big Board in the second calendar quarter of 2009. Upon transfer the stock will trade under the new ticker symbol "MGX."
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
US FDA approves SEROQUEL XR for add-on treatment of Major Depressive Disorder
AstraZeneca, 12/07/09
FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taros Proprietary Non-Sedating Barbiturate Compound
Taro Pharmaceuticals USA, 12/07/09
Article Search
Sponsor